

- Acetaminophen-aspirin-caffeine, 2590, 2592t
 Acetate, 98e-5t
 Acetazolamide
 action of, 332e-7
 for acute angle-closure glaucoma, 200
 adverse effects of, 297, 380
 for altitude illness, 476e-2, 476e-2t, 476e-4, 476e-5
 for episodic ataxia, 2630
 for hyperkalemia, 64e-3
 for hyperkalemic periodic paralysis, 462e-18
 for hypokalemic periodic paralysis, 462e-17
 for metabolic alkalosis, 322
 for paroxysmal symptoms in MS, 2672
 for pseudotumor cerebri, 203
 for raised CSF pressure headache, 110
 for salicylate-induced acidosis, 319
 for tumoral calcinosis, 426e-8
 for uric acid nephropathy, 431e-5
 Acetoacetate, 318
 Acetohydroxamic acid, 1871
 Acetylcholine (ACh)
 action of, 444e-3t, 2637
 clinical aspects of, 444e-3t
 deficiency of, in delirium, 167
 in neural control of gastrointestinal system, 264
 structure of, 444e-3t
 in swallowing, 255
 Acetylcholine receptor (AChR)
 in congenital myasthenic syndromes, 2702, 2703t
 in myasthenia gravis, 372e-24t, 377e-4, 2701, 2701f
 Acetylcholinesterase (AChE)
 deficiencies of, 2702, 2703t
 in nerve agent exposure, 262e-4, 262e-4f
 test, in myasthenia gravis, 2702
 Acetylcholinesterase (AChE) inhibitors
 for gastroparesis, 260t, 261
 overdose/poisoning with, 473e-10t
 for snakebite treatment, 2737, 2737t
 N-Acetylglutamate synthase deficiency, 434e-3t
 N-Acetyltransferase, 34t
 ACh. *See* Acetylcholine (ACh)
 Achalasia, **1904**
 chronic, esophageal cancer and, 532
 clinical features of, 1904
 diagnosis of, 1904, 1905f
 differential diagnosis of, 1904
 dysphagia in, 256
 LES relaxation impairment in, 1904, 1905f
 subtypes of, 1905f
 treatment of, 258, 1905
 AChE. *See* Acetylcholinesterase (AChE)
 Achilles bursitis, 2247
 Achlorhydria, 350e-1
 Achondrodysplasia, 426e-7
 Achondroplasia, 2512
 AChR. *See* Acetylcholine receptor (AChR)
 Achromatopsia, 182, 197
Achromobacter xylosoxidans, 183e-2, 183e-2t
 Acid anhydride exposure, 1692, 1692t
 Acid-base disorders, **315**. *See also specific disorders*
 anion gap in, 64e-8, 317
 approach to the patient, 317, 317t
 mixed, 64e-1, 64e-8, 316-317, 316t
 simple, 315-316
 Acid-base homeostasis, 315
 Acid-base nomogram, 316, 316f
 Acidemia, 309, 434e-1, 2092
 Acid-fast bacteria, 150e-1-2
 Acid fume exposure, 1692t
 Acid maltase (acid α -glucosidase) deficiency.
 See Pompe disease
 Aciduria, orotic, 431e-5t, 431e-6, 431e-6f
Acinetobacter spp., 150e-2t, 934, 1036
Acinetobacter spp. infections, **1036**
 antibiotic resistance in, 1037
 approach to the patient, 1037
 burn-wound, 166e-1
 in cancer patient, 486t, 487
 clinical features of, 1037
 complications of, 1038
 diagnosis of, 1037
 epidemiology of, 1036
 etiology of, 1036
 global considerations in, 1036, 1037
 health care-associated pneumonia, 803t, 914
 pathogenesis of, 1036-1037
 prevention of, 1038
 prognosis of, 1038
 in returning war veterans, 152e-5t, 152e-9
 treatment of, 152e-5t, 152e-9, 940t, 1037-1038, 1037t
 urinary tract, 862
 ventilator-associated pneumonia, 811, 915
 ACIP (Advisory Committee on Immunization Practices), 786
 Acitretin
 adverse effects of, 348t, 354, 380
 for pityriasis rubra pilaris, 354t
 for psoriasis, 348, 348t
 aCL (anticardiolipin antibodies), 2131, 2135t, 2754t
 ACLS (advanced cardiac life support), 1769-1770, 1769f
 ACMV (assist control ventilation), 1741, 1742t.
 See also Mechanical ventilation
 Acneiform eruptions, 356, 356t
 Acne rosacea, **352**
 clinical features of, 76e-1f, 341t, 342f, 352, 352f
 treatment of, 352
 Acne vulgaris, **351**
 in 21-hydroxylase deficiency, 2355
 clinical features of, 76e-1f, 341t, 342f, 351-352, 352f
 drugs exacerbating, 378
 folliculitis in, 829
 pathophysiology of, 351
 treatment of, 352
 Acotiamide, 263
 Acoustic neuroma. *See* Vestibular schwannoma (acoustic neuroma)
 Acoustic reflex, 222
 Acoustic reflex decay, 223
 ACP Journal Club, 25t
 Acral angiodermatitis, 367
 Acral erythema, drug-induced, 380
 Acrocephalopolysyndactyly (Pfeiffer syndrome), 435
 Acrochordon, 341t, 342f, 359
 Acrocyanosis, 1442, 1648f, **1649**, 1754
 Acrodermatitis chronica atrophicans, 1151
 Acrodermatitis enteropathica, 96e-9
 Acrolelin exposure, 1692t
 Acromegaly, **2269**
 clinical features of, 359, 462e-19, 2269, 2270f
 arthropathy, 2240-2241
 cardiac, 290e-1t, 290e-3
 hirsutism, 332
 hypertension, 1620
 oral, 236
 diagnosis of, 2269
 etiology of, 2240, 2269, 2269t
 familial, 2266
 in GRFoma, 571
 laboratory investigation of, 2269
 vs. pachydermoperiostosis, 426e-7
 paraneoplastic, 609t
 screening tests for, 2262t
 treatment of, 2269-2271, 2270f
 Acro-osteolysis, 2160, 2160f
 Acropachy, thyroid, 2245, 2295, 2295f
 Acroparesthesia, in Fabry's disease, 432e-1
 Acrylamide, 2688t
 Acta, 982
 ACTA1 gene, 462e-12
 ACTH. *See* Adrenocorticotropic hormone (ACTH)
 ACTHoma, 559t, 571
 ACTH stimulation test, 2310
 Actin, 265e-5, 265e-5f, 372e-24t, 1555t, 1556f
 Actinic dermatitis, 389
 Actinic keratosis
 clinical features of, 76e-6f, 341t, 342f, 501f
 malignant conversion of, 387, 501
 sun avoidance and, 476
 treatment of, 386
Actinobacillus spp. *See* *Aggregatibacter* spp.
Actinomyces spp., 150e-2t, 1088. *See also* Actinomycosis
 Actinomycosis, 1089
 Actinomyces-like organisms, 1089
Actinomyces pyogenes, 981
 Actinomycetoma, nocardial, 1085-1086, 1086f, 1087t. *See also* *Nocardia* spp. infections
 Actinomycosis, **1088**
 clinical features of
 abdominal, 1089
 CNS, 907t, 1089
 disseminated, 1090
 in dog-bite wound, 167e-1
 hepatic-splenic, 1089, 1090f
 musculoskeletal and soft tissue, 1089-1090
 oral-cervicofacial, 239t, 241, 1088, 1089f, 1097
 pelvic, 1089, 1090f
 thoracic, 1088-1089, 1089f
 diagnosis of, 150e-1, 150e-2t, 1090
 epidemiology of, 1088
 etiology of, 1088
 pathogenesis of, 1088
 treatment of, 1090-1091, 1091t
 Action Plan to Prevent Healthcare-Associated Infections, 912, 913t
 Action potentials, cardiac
 electrophysiology of, 273e-1-2, 273e-1f
 phases of, 265e-6
 regional differences in, 1466, 1466f, 1467f
 Action spectrum, 385
 Activase. *See* Alteplase
 Activated charcoal
 for indigestion, 263
 for paralytic shellfish poisoning, 2743
 for poisoning/drug overdose, 473e-6, 473e-7
 Activated partial thromboplastin time (aPTT)
 causes of abnormal values, 406t
 in coagulation disorders, 732, 733t, 735
 coagulation factors tested in, 405-406, 406f, 733f
 LA-PTT, 406
 for monitoring heparin therapy, 750-751
 in preoperative testing, 405
 prolonged, 406t
 reagent composition of, 406
 reference values for, 2755t
 Activated protein C, recombinant, 1758
 Activator protein-1, in asthma, 1674
 Active transport, 332e-6, 1933
 Activin, 401e-4
 Activities of daily living (ADLs), 72t, 78t
 Acupressure, 14e-1t, 261, 1880
 Acupuncture, 14e-1t, 14e-3, 120, 338
 Acustimulation, 1880
 Acute brain failure. *See* Delirium
 Acute chest syndrome, 634, 635-636
 Acute confusional state. *See* Delirium
 Acute coronary syndromes
 diagnosis of, 1599, 1599f
 evaluation and management of, 1595, 1595f
 hyperbaric oxygen therapy for, 477e-4t
 myocardial infarction
 non-ST-segment elevation. *See* Non-ST-segment elevation acute coronary syndrome (NSTE-ACS)
 ST-segment elevation. *See* ST-segment elevation myocardial infarction (STEMI)
 PCI for, 296e-4. *See also* Percutaneous coronary interventions (PCI)
 pulmonary edema in, 1764
 unstable angina, 96, 96t, 97, 1593. *See also* Non-ST-segment elevation acute coronary syndrome (NSTE-ACS)
 Acute disseminated encephalomyelitis (ADEM), 441e-26f, **2673**